Dallas' Nanoscope Therapeutics Hires Chief Technology, Manufacturing Officer

Raymond Kaczmarek

Industry veteran Ray Kaczmarek has joined Dallas-based Nanoscope Therapeutics as chief technology and manufacturing officer.

Nanoscope is a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and geographic atrophy. The company said Kaczmarek is a recognized expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotechnology companies.

“Ray brings a wealth of expertise in building and sustaining gene therapy manufacturing programs. His operational leadership will be crucial to developing the commercial supply of our future therapies as we advance towards potential commercialization,” Sulagna Bhattacharya, co-founder and CEO of Nanoscope, said in a statement.

Nanoscope said that Kaczmarek has an extensive background of executive leadership and operational expertise in the gene therapy manufacturing industry.

Former CEO of Genezen

Most recently, he was CEO of Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector process development, GMP manufacturing, and analytical services. Before Genezen, Kaczmarek served as vice president of GMP Operations at TriLink Biotechnologies, part of Maravai Lifesciences, a CDMO specializing in the synthesis of nucleic acids, GMP capping reagents, plasmids, and oligonucleotides.

Kaczmarek also was vice president of manufacturing and supply chain operations at Pacira Biosciences, a leading provider of non-opioid pain management and regenerative health solutions, and, before that, he was president of Nitto Avecia, a CDMO specializing in end-to-end solutions for oligonucleotide programs.

“Nanoscope has reached a pivotal juncture in its mission to bring transformative gene therapy products to market,” Kaczmarek said in a statement. “I’m excited to contribute my expertise to Nanoscope’s programs, and I look forward to leading the build-out of commercial product manufacturing to ensure Nanoscope is ready to bring these much-needed treatments to patients.”

Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists.

Get on the list.
Dallas Innovates, every day.

R E A D N E X T

Addison Private School Promotes Technology Leader as First-Ever Chief Innovation Officer
Trinity Christian Academy has named Lisa Wong, a former Raytheon engineer and TCA’s director of technology, as its first chief innovation officer. Wong will lead the integration of cutting-edge technology, foster innovation, and prepare students for future careers.
Starr Conspiracy Rebrands to TSC, Names Longtime Exec as New CEO
Fort Worth-based marketing agency The Starr Conspiracy has officially rebranded as TSC, signaling a new era with fresh leadership. CEO Ashley Bernard is steering the agency toward innovation, AI investment, and cutting-edge marketing strategies, with the rebrand unveiled at the 2024 HR Technology Conference & Exposition.
SignaPay Adds Industry Veteran as Chief Technology Officer
SignaPay, an Irving-based payments processing provider, has added David Leppek as chief technology officer. In this role, Leppek will manage all information technology functions for the organization, including developing and improving SignaPay's proprietary gateway, risk management, and CRM platforms. CEO John Martillo welcomed Leppek to the SignaPay executive leadership team, saying in a statement, "His stellar reputation in the payments space and extensive experience leading technology teams will be invaluable as we continue to scale our business and provide best-of-class solutions." Martillo added that he looks forward to Leppek's contributions during SignaPay's "extraordinary growth." According to SignaPay, Leppek is a…
WWEX Group Names New Chief Technology Officer, Appoints New CIO
As CTO, Daniel Curling will play a key role in shaping the future growth of the company and driving technological advancements. As CIO, Scott Ball will be responsible for WWEX Group's technology infrastructure, operations, security, and corporate applications.
Dallas-Based HEST Investments Leads $1.8M SPV Investment in Secretome Therapeutics
Baltimore-based Secretome has a presence at BioLabs at Pegasus Park in Dallas. The biotech company is at the forefront of developing "revolutionary solutions" aimed at harnessing the power of secretomes, naturally occurring molecules that promote healing and regeneration, HEST said.